Could an oral drug boost immunotherapy in tough melanoma cases?
NCT ID NCT02816021
First seen Feb 23, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This phase 2 study tested a combination of oral azacitidine (a chemotherapy-like drug) and pembrolizumab (an immunotherapy) in 24 people with advanced melanoma that had spread. The goal was to see if the combo could shrink tumors or slow the disease, both in patients who had never received PD-1 inhibitors and in those whose cancer had progressed on them. Participants took azacitidine pills for 15 days each cycle and received pembrolizumab infusions every 3 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77330, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
azacitidine and pembrolizumab
What this could lead to
If it works, this combination could offer a new treatment option for patients with advanced melanoma, especially those whose cancer has stopped responding to standard immunotherapy.
What could go wrong
This is a small, early-phase study with only 24 participants. The combination may not improve outcomes and could cause additional side effects from the two drugs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.